Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Its worldwide prevalence is rapidly increasing and is currently estimated at 24%. NAFLD is highly associated with many features of the metabolic syndrome, including obesity, insulin resistance, hyperlipidaemia, and hypertension. The pathogenesis of NAFLD is complex and not fully understood, but there is increasing evidence that the gut microbiota is strongly implicated in the development of NAFLD. In this review, we discuss the major factors that induce dysbiosis of the gut microbiota and disrupt intestinal permeability, as well as possible mechanisms leading to the development of NAFLD. We also discuss the most consistent NAFLD-associated gut microbiota signatures and immunological mechanisms involved in maintaining the gut barrier and liver tolerance to gut-derived factors. Gut-derived factors, including microbial, dietary, and host-derived factors involved in NAFLD pathogenesis, are discussed in detail. Finally, we review currently available diagnostic and prognostic methods, summarise latest knowledge on promising microbiota-based biomarkers, and discuss therapeutic strategies to manipulate the microbiota, including faecal microbiota transplantation, probiotics and prebiotics, deletions of individual strains with bacteriophages, and blocking the production of harmful metabolites.

Czech Academy of Sciences Institute of Microbiology 142 20 Prague Czech Republic

NEXARS The Campus Science Park 625 00 Brno Czech Republic

The Faculty of Medicine in Hradec Kralove Charles University Prague 500 03 Hradec Kralove Czech Republic

See more in PubMed

European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes. Facts. 2016;9:65–90. doi: 10.1159/000443344. PubMed DOI PMC

Bajaj J.S. Alcohol, liver disease and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 2019;16:235–246. doi: 10.1038/s41575-018-0099-1. PubMed DOI

Ballestri S., Nascimbeni F., Romagnoli D., Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol. Res. 2016;46:1074–1087. doi: 10.1111/hepr.12656. PubMed DOI

Stepanova M., Rafiq N., Makhlouf H., Agrawal R., Kaur I., Younoszai Z., McCullough A., Goodman Z., Younossi Z.M. Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) Dig. Dis. Sci. 2013;58:3017–3023. doi: 10.1007/s10620-013-2743-5. PubMed DOI

Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Järvinen H., Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis. 2010;42:320–330. doi: 10.1016/j.dld.2010.01.016. PubMed DOI

Athyros V.G., Alexandrides T.K., Karagiannis A., Karvounis C., Katsiki N., Kotsis V., Kountouras J., Liberopoulos E., Pitsavos C., Polyzos S., et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;71:17–32. doi: 10.1016/j.metabol.2017.02.014. PubMed DOI

Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. doi: 10.1002/hep.28431. PubMed DOI

Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018;15:11–20. doi: 10.1038/nrgastro.2017.109. PubMed DOI

Betrapally N.S., Gillevet P.M., Bajaj J.S. Gut microbiome and liver disease. Transl. Res. 2017;179:49–59. doi: 10.1016/j.trsl.2016.07.005. PubMed DOI PMC

Carding S., Verbeke K., Vipond D.T., Corfe B.M., Owen L.J. Dysbiosis of the gut microbiota in disease. Microb. Ecol. Health Dis. 2015;26:26191. doi: 10.3402/mehd.v26.26191. PubMed DOI PMC

Shen F., Zheng R.-D., Sun X.-Q., Ding W.-J., Wang X.-Y., Fan J.-G. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat. Dis. Int. 2017;16:375–381. doi: 10.1016/S1499-3872(17)60019-5. PubMed DOI

Zhu L., Baker S.S., Gill C., Liu W., Alkhouri R., Baker R.D., Gill S.R. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2013;57:601–609. doi: 10.1002/hep.26093. PubMed DOI

Shin N.-R., Whon T.W., Bae J.-W. Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33:496–503. doi: 10.1016/j.tibtech.2015.06.011. PubMed DOI

Gomez A., Petrzelkova K.J., Burns M.B., Yeoman C.J., Amato K.R., Vlckova K., Modry D., Todd A., Robinson C.A.J., Remis M.J., et al. Gut Microbiome of Coexisting BaAka Pygmies and Bantu Reflects Gradients of Traditional Subsistence Patterns. Cell Rep. 2016;14:2142–2153. doi: 10.1016/j.celrep.2016.02.013. PubMed DOI

Mancabelli L., Milani C., Lugli G.A., Turroni F., Ferrario C., Van Sinderen D., Ventura M. Meta-analysis of the human gut microbiome from urbanized and pre-agricultural populations. Environ. Microbiol. 2017;19:1379–1390. doi: 10.1111/1462-2920.13692. PubMed DOI

Kostovcikova K., Coufal S., Galanova N., Fajstova A., Hudcovic T., Kostovcik M., Prochazkova P., Zakostelska Z.J., Cermakova M., Sediva B., et al. Diet Rich in Animal Protein Promotes Pro-inflammatory Macrophage Response and Exacerbates Colitis in Mice. Front. Immunol. 2019;10:919. doi: 10.3389/fimmu.2019.00919. PubMed DOI PMC

Fajstova A., Galanova N., Coufal S., Malkova J., Kostovcik M., Cermakova M., Pelantova H., Kuzma M., Sediva B., Hudcovic T., et al. Diet Rich in Simple Sugars Promotes Pro-Inflammatory Response via Gut Microbiota Alteration and TLR4 Signaling. Cells. 2020;9:2701. doi: 10.3390/cells9122701. PubMed DOI PMC

Hrncirova L., Machova V., Trckova E., Krejsek J., Hrncir T. Food Preservatives Induce Proteobacteria Dysbiosis in Human-Microbiota Associated Nod2-Deficient Mice. Microorganisms. 2019;7:383. doi: 10.3390/microorganisms7100383. PubMed DOI PMC

Hrncirova L., Hudcovic T., Sukova E., Machova V., Trckova E., Krejsek J., Hrncir T. Human gut microbes are susceptible to antimicrobial food additives in vitro. Folia Microbiol. 2019;64:497–508. doi: 10.1007/s12223-018-00674-z. PubMed DOI

Chassaing B., Van De Wiele T., De Bodt J., Marzorati M., Gewirtz A.T. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut. 2017;66:1414–1427. doi: 10.1136/gutjnl-2016-313099. PubMed DOI PMC

Rodriguez-Palacios A., Harding A., Menghini P., Himmelman C., Retuerto M., Nickerson K.P., Lam M., Croniger C.M., McLean M.H., Durum S.K., et al. The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn’s Disease–Like Ileitis. Inflamm. Bowel Dis. 2018;24:1005–1020. doi: 10.1093/ibd/izy060. PubMed DOI PMC

Gatea F., Sârbu I., Vamanu E. In Vitro Modulatory Effect of Stevioside, as a Partial Sugar Replacer in Sweeteners, on Human Child Microbiota. Microorganisms. 2021;9:590. doi: 10.3390/microorganisms9030590. PubMed DOI PMC

Suez J., Korem T., Kuperman Y., Harmelin A., Kolodkin-Gal I., Shapiro H., Halpern Z., Segal E., Elinav E., Zeevi D., et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014;514:181–186. doi: 10.1038/nature13793. PubMed DOI

Catanzaro J.R., Strauss J.D., Bielecka A., Porto A.F., Lobo F.M., Urban A., Schofield W.B., Palm N.W. IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM. Sci. Rep. 2019;9:1–10. doi: 10.1038/s41598-019-49923-2. PubMed DOI PMC

Levy M., Kolodziejczyk A.A., Thaiss C.A., Elinav E. Dysbiosis and the immune system. Nat. Rev. Immunol. 2017;17:219–232. doi: 10.1038/nri.2017.7. PubMed DOI

Chu H., Duan Y., Yang L., Schnabl B. Small metabolites, possible big changes: A microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2018;68:359–370. doi: 10.1136/gutjnl-2018-316307. PubMed DOI

Llorente C., Schnabl B. The Gut Microbiota and Liver Disease. Cell. Mol. Gastroenterol. Hepatol. 2015;1:275–284. doi: 10.1016/j.jcmgh.2015.04.003. PubMed DOI PMC

Png C.W., Lindén S.K., Gilshenan K.S., Zoetendal E.G., McSweeney C.S., Sly L.I., McGuckin M.A., Florin T.H.J. Mucolytic Bacteria with Increased Prevalence in IBD Mucosa Augment In Vitro Utilization of Mucin by Other Bacteria. Am. J. Gastroenterol. 2010;105:2420–2428. doi: 10.1038/ajg.2010.281. PubMed DOI

Aron-Wisnewsky J., Vigliotti C., Witjes J., Le P., Holleboom A.G., Verheij J., Nieuwdorp M., Clément K. Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol. 2020;17:279–297. doi: 10.1038/s41575-020-0269-9. PubMed DOI

Loomba R., Seguritan V., Li W., Long T., Klitgord N., Bhatt A., Dulai P.S., Caussy C., Bettencourt R., Highlander S.K., et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25:1054–1062.e5. doi: 10.1016/j.cmet.2017.04.001. PubMed DOI PMC

Qin N., Yang F., Li A., Prifti E., Chen Y., Shao L., Guo J., Le Chatelier E., Yao J., Wu L., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59–64. doi: 10.1038/nature13568. PubMed DOI

Le Chatelier E., Nielsen T., Qin J., Prifti E., Hildebrand F., Falony G., Almeida M., Arumugam M., Batto J.-M., Kennedy S., et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–546. doi: 10.1038/nature12506. PubMed DOI

Karlsson F.H., Tremaroli V., Nookaew I., Bergström G., Behre C.J., Fagerberg B., Nielsen J., Bäckhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103. doi: 10.1038/nature12198. PubMed DOI

Sokol H., Seksik P., Furet J.P., Firmesse O., Nion-Larmurier I., Beaugerie L., Cosnes J., Corthier G., Marteau P., Doré J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 2009;15:1183–1189. doi: 10.1002/ibd.20903. PubMed DOI

Rajilić–Stojanović M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M. Global and Deep Molecular Analysis of Microbiota Signatures in Fecal Samples From Patients with Irritable Bowel Syndrome. Gastroenterology. 2011;141:1792–1801. doi: 10.1053/j.gastro.2011.07.043. PubMed DOI

Aron-Wisnewsky J., Prifti E., Belda E., Ichou F., Kayser B.D., Dao M.C., Verger E.O., Hedjazil L., Bouillot J.-L., Chevallier J.-M., et al. Major microbiota dysbiosis in severe obesity: Fate after bariatric surgery. Gut. 2019;68:70–82. doi: 10.1136/gutjnl-2018-316103. PubMed DOI PMC

Yang A.-M., Inamine T., Hochrath K., Chen P., Wang L., Llorente C., Bluemel S., Hartmann P., Xu J., Koyama Y., et al. Intestinal fungi contribute to development of alcoholic liver disease. J. Clin. Investig. 2017;127:2829–2841. doi: 10.1172/JCI90562. PubMed DOI PMC

Hoyles L., Fernandez-Real J.-M., Federici M., Serino M., Abbott J., Charpentier J., Heymes C., Luque J.L., Anthony E., Barton R.H. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat. Med. 2018;24:1070–1080. doi: 10.1038/s41591-018-0061-3. PubMed DOI PMC

Raman M., Ahmed I., Gillevet P.M., Probert C.S., Ratcliffe N.M., Smith S., Greenwood R., Sikaroodi M., Lam V., Crotty P., et al. Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans with Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2013;11:868–875.e3. doi: 10.1016/j.cgh.2013.02.015. PubMed DOI

Michail S., Lin M., Frey M.R., Fanter R., Paliy O., Hilbush B., Reo N.V. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol. Ecol. 2014;91:1–9. doi: 10.1093/femsec/fiu002. PubMed DOI PMC

Wong V.W.-S., Tse C.-H., Lam T.T.-Y., Wong G.L.-H., Chim A.M.-L., Chu W.C.-W., Yeung D.K.-W., Law P.T.-W., Kwan H.-S., Yu J., et al. Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis–A Longitudinal Study. PLoS ONE. 2013;8:e62885. doi: 10.1371/journal.pone.0062885. PubMed DOI PMC

Del Chierico F., Nobili V., Vernocchi P., Russo A., De Stefanis C., Gnani D., Furlanello C., Zandonà A., Paci P., Capuani G., et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65:451–464. doi: 10.1002/hep.28572. PubMed DOI

Wang B., Jiang X., Cao M., Ge J., Bao Q., Tang L., Chen Y., Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci. Rep. 2016;6:32002. doi: 10.1038/srep32002. PubMed DOI PMC

Mouzaki M., Comelli E.M., Arendt B.M., Bonengel J., Fung S.K., Fischer S.E., McGilvray I.D., Allard J.P. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120–127. doi: 10.1002/hep.26319. PubMed DOI

Boursier J., Mueller O., Hunault G., Oberti F., Calès P., Diehl A.M., Barret M., Machado M.V., Fizanne L., Araujo-Perez F., et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–775. doi: 10.1002/hep.28356. PubMed DOI PMC

Da Silva H.E., Teterina A., Comelli E.M., Taibi A., Arendt B.M., Fischer S.E., Lou W., Allard J.P. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci. Rep. 2018;8:1–12. doi: 10.1038/s41598-018-19753-9. PubMed DOI PMC

Alferink L.J., Radjabzadeh D., Erler N.S., Vojinovic D., Medina-Gomez C., Uitterlinden A.G., de Knegt R.J., Amin N., Ikram M.A., Janssen H.L., et al. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1355 Adults. Hepatology. 2021;73:968–982. doi: 10.1002/hep.31417. PubMed DOI

Chen Y., Yang F., Lu H., Wang B., Chen Y., Lei D., Wang Y., Zhu B., Li L. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–572. doi: 10.1002/hep.24423. PubMed DOI

Schierwagen R., Alvarez-Silva C., Madsen M.S.A., Kolbe C.C., Meyer C., Thomas D., Uschner F.E., Magdaleno F., Jansen C., Pohlmann A., et al. Circulating microbiome in blood of different circulatory compartments. Gut. 2019;68:578–580. doi: 10.1136/gutjnl-2018-316227. PubMed DOI

Brandtzaeg P., Prydz H. Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature. 1984;311:71–73. doi: 10.1038/311071a0. PubMed DOI

Mestecky J., Russell M.W., Elson C.O. Intestinal IgA: Novel views on its function in the defence of the largest mucosal surface. Gut. 1999;44:2–5. doi: 10.1136/gut.44.1.2. PubMed DOI PMC

Gautreaux M.D., Deitch E.A., Berg R.D. T lymphocytes in host defense against bacterial translocation from the gastrointestinal tract. Infect. Immun. 1994;62:2874–2884. doi: 10.1128/IAI.62.7.2874-2884.1994. PubMed DOI PMC

Johnson R.J., Rivard C., Lanaspa M.A., Otabachian-Smith S., Ishimoto T., Cicerchi C., Cheeke P.R., MacIntosh B., Hess T. Fructokinase, Fructans, Intestinal Permeability, and Metabolic Syndrome: An Equine Connection? J. Equine Veter. Sci. 2013;33:120–126. doi: 10.1016/j.jevs.2012.05.004. PubMed DOI PMC

Spruss A., Bergheim I. Dietary fructose and intestinal barrier: Potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2009;20:657–662. doi: 10.1016/j.jnutbio.2009.05.006. PubMed DOI

Bergheim I., Weber S., Vos M., Krämer S., Volynets V., Kaserouni S., McClain C.J., Bischoff S.C. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J. Hepatol. 2008;48:983–992. doi: 10.1016/j.jhep.2008.01.035. PubMed DOI

Crispe I.N. Liver antigen-presenting cells. J. Hepatol. 2011;54:357–365. doi: 10.1016/j.jhep.2010.10.005. PubMed DOI PMC

Horst A.K., Neumann K., Diehl L., Tiegs G. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell. Mol. Immunol. 2016;13:277–292. doi: 10.1038/cmi.2015.112. PubMed DOI PMC

Karimi M.H., Geramizadeh B., Malek-Hosseini S.A. Tolerance Induction in Liver. Int. J. Organ Transplant. Med. 2015;6:45–54. PubMed PMC

Breous E., Somanathan S., Vandenberghe L.H., Wilson J.M. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology. 2009;50:612–621. doi: 10.1002/hep.23043. PubMed DOI PMC

Carambia A., Freund B., Schwinge D., Heine M., Laschtowitz A., Huber S., Wraith D.C., Korn T., Schramm C., Lohse A.W., et al. TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. J. Hepatol. 2014;61:594–599. doi: 10.1016/j.jhep.2014.04.027. PubMed DOI

Crispe I.N. Immune tolerance in liver disease. Hepatology. 2014;60:2109–2117. doi: 10.1002/hep.27254. PubMed DOI PMC

Doherty D.G. Antigen-specific immune tolerance in the liver. Nat. Biomed. Eng. 2019;3:763–765. doi: 10.1038/s41551-019-0445-9. PubMed DOI

Isayama F., Hines I.N., Kremer M., Milton R.J., Byrd C.L., Perry A.W., McKim S.E., Parsons C., Rippe R.A., Wheeler M.D. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2006;290:G1318–G1328. doi: 10.1152/ajpgi.00405.2005. PubMed DOI

Gäbele E., Mühlbauer M., Dorn C., Weiss T.S., Froh M., Schnabl B., Wiest R., Schölmerich J., Obermeier F., Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem. Biophys. Res. Commun. 2008;376:271–276. doi: 10.1016/j.bbrc.2008.08.096. PubMed DOI

Lebeaupin C., Proics E., De Bieville C.H.D., Rousseau D., Bonnafous S., Patouraux S., Adam G., Lavallard V.J., Rovere C., Le Thuc O., et al. ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis. 2015;6:e1879. doi: 10.1038/cddis.2015.248. PubMed DOI PMC

Ghazarian M., Revelo X.S., Nøhr M.K., Luck H., Zeng K., Lei H., Tsai S., Schroer S.A., Park Y.J., Chng M.H.Y., et al. Type I interferon responses drive intrahepatic T cells to promote metabolic syndrome. Sci. Immunol. 2017;2:eaai7616. doi: 10.1126/sciimmunol.aai7616. PubMed DOI PMC

Studer N., Desharnais L., Beutler M., Brugiroux S., Terrazos M.A., Menin L., Schürch C.M., McCoy K.D., Kuehne S.A., Minton N.P., et al. Functional Intestinal Bile Acid 7α-Dehydroxylation by Clostridium scindens Associated with Protection from Clostridium difficile Infection in a Gnotobiotic Mouse Model. Front. Cell. Infect. Microbiol. 2016;6:191. doi: 10.3389/fcimb.2016.00191. PubMed DOI PMC

Zhu W., Gregory J.C., Org E., Buffa J.A., Gupta N., Wang Z., Li L., Fu X., Wu Y., Mehrabian M., et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell. 2016;165:111–124. doi: 10.1016/j.cell.2016.02.011. PubMed DOI PMC

Yajima M., Karaki S.-I., Tsuruta T., Kimura S., Nio-Kobayashi J., Kuwahara A., Yajima T. Diversity of the intestinal microbiota differently affects non-neuronal and atropine-sensitive ileal contractile responses to short-chain fatty acids in mice. Biomed. Res. 2016;37:319–328. doi: 10.2220/biomedres.37.319. PubMed DOI

Johnson R.J., Segal M.S., Sautin Y., Nakagawa T., Feig D.I., Kang D.-H., Gersch M.S., Benner S., Sánchez-Lozada L.G. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am. J. Clin. Nutr. 2007;86:899–906. PubMed

Jensen T., Abdelmalek M.F., Sullivan S., Nadeau K.J., Green M., Roncal C., Nakagawa T., Kuwabara M., Sato Y., Kang D.-H., et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J. Hepatol. 2018;68:1063–1075. doi: 10.1016/j.jhep.2018.01.019. PubMed DOI PMC

Li J.-M., Yu R., Zhang L.-P., Wen S.-Y., Wang S.-J., Zhang X.-Y., Xu Q., Kong L.-D. Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation: A benefit of short-chain fatty acids. Microbiome. 2019;7:98. doi: 10.1186/s40168-019-0713-7. PubMed DOI PMC

Mäenpää P.H., Raivio K.O., Kekomäki M.P. Liver Adenine Nuldeotides: Fructose-Induced Depletion and Its Effect on Protein Synthesis. Science. 1968;161:1253–1254. doi: 10.1126/science.161.3847.1253. PubMed DOI

Abdelmalek M.F., Lazo M., The Fatty Liver Subgroup of the Look AHEAD Research Group. Horska A., Bonekamp S., Lipkin E.W., Balasubramanyam A., Bantle J.P., Johnson R.J., Diehl A.M., et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology. 2012;56:952–960. doi: 10.1002/hep.25741. PubMed DOI PMC

Bawden S., Stephenson M., Ciampi E., Hunter K., Marciani L., Macdonald I., Aithal G., Morris P., Gowland P. Investigating the effects of an oral fructose challenge on hepatic ATP reserves in healthy volunteers: A 31P MRS study. Clin. Nutr. 2016;35:645–649. doi: 10.1016/j.clnu.2015.04.001. PubMed DOI

Berghe G.V.D. Fructose: Metabolism and short-term effects on carbohydrate and purine metabolic pathways. Prog. Biochem. Pharmacol. 1986;21:1–32. PubMed

Le M.T., Frye R.F., Rivard C.J., Cheng J., McFann K.K., Segal M.S., Johnson R.J., Johnson J.A. Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. Metabolism. 2012;61:641–651. doi: 10.1016/j.metabol.2011.09.013. PubMed DOI PMC

Lanaspa M.A., Sanchez-Lozada L.G., Choi Y.-J., Cicerchi C., Kanbay M., Roncal-Jimenez C.A., Ishimoto T., Li N., Marek G., Duranay M., et al. Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress: Potential Role in Fructose-Dependent and- Independent Fatty Liver. J. Biol. Chem. 2012;287:40732–40744. doi: 10.1074/jbc.M112.399899. PubMed DOI PMC

Lim J.S., Mietus-Snyder M., Valente A., Schwarz J.-M., Lustig R.H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 2010;7:251–264. doi: 10.1038/nrgastro.2010.41. PubMed DOI

Lanaspa M.A., Cicerchi C., Garcia G., Li N., Roncal-Jimenez C.A., Rivard C.J., Hunter B., Andrés-Hernando A., Ishimoto T., Sánchez-Lozada L.G., et al. Counteracting Roles of AMP Deaminase and AMP Kinase in the Development of Fatty Liver. PLoS ONE. 2012;7:e48801. doi: 10.1371/journal.pone.0048801. PubMed DOI PMC

Yao Z., Vance D.E. Reduction in VLDL, but not HDL, in plasma of rats deficient in choline. Biochem. Cell Biol. 1990;68:552–558. doi: 10.1139/o90-079. PubMed DOI

Blumberg H., Mccollum E.V., Albanese A.A., Buschke W. The prevention by choline of liver cirrhosis in rats on high fat, low protein diets. Science. 1941;93:598–599. doi: 10.1126/science.93.2425.598. PubMed DOI

Sanders L.M., Zeisel S.H. Choline: Dietary Requirements and Role in Brain Development. Nutr. Today. 2007;42:181–186. doi: 10.1097/01.NT.0000286155.55343.fa. PubMed DOI PMC

Shaw G.M., Finnell R.H., Blom H.J., Carmichael S.L., Vollset S.E., Yang W., Ueland P.M. Choline and Risk of Neural Tube Defects in a Folate-fortified Population. Epidemiology. 2009;20:714–719. doi: 10.1097/EDE.0b013e3181ac9fe7. PubMed DOI

Rath S., Heidrich B., Pieper D.H., Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome. 2017;5:54. doi: 10.1186/s40168-017-0271-9. PubMed DOI PMC

Zeisel S.H., Dacosta K.A., Youssef M., Hensey S. Conversion of Dietary Choline to Trimethylamine and Dimethylamine in Rats: Dose-Response Relationship. J. Nutr. 1989;119:800–804. doi: 10.1093/jn/119.5.800. PubMed DOI

Wang Z., Klipfell E., Wu Y., Schauer P., Smith J.D., Allayee H., Tang W.H.W., DiDonato J.A., Lusis A.J., Hazen S.L., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63. doi: 10.1038/nature09922. PubMed DOI PMC

Chen Y.-M., Liu Y., Zhou R.-F., Chen X.-L., Wang C., Tan X.-Y., Wang L.-J., Zheng R.-D., Zhang H.-W., Ling W.-H., et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci. Rep. 2016;6:19076. doi: 10.1038/srep19076. PubMed DOI PMC

Dumas M.-E., Barton R.H., Mitchell S.C., Holmes E., McCarthy M.I., Scott J., Gauguier D., Nicholson J.K., Toye A., Cloarec O., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl. Acad. Sci. USA. 2006;103:12511–12516. doi: 10.1073/pnas.0601056103. PubMed DOI PMC

Gao X., Liu X., Xu J., Xue C., Xue Y., Wang Y. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J. Biosci. Bioeng. 2014;118:476–481. doi: 10.1016/j.jbiosc.2014.03.001. PubMed DOI

Koeth R.A., Wang Z., Levison B.S., Buffa J.A., Org E., Sheehy B.T., Britt E.B., Fu X., Wu Y., Li L., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013;19:576–585. doi: 10.1038/nm.3145. PubMed DOI PMC

Baxter N.T., Schmidt A.W., Venkataraman A., Kim K.S., Waldron C., Schmidt T.M. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. mBio. 2019;10:e02566-18. doi: 10.1128/mBio.02566-18. PubMed DOI PMC

Perry R.J., Peng L., Barry N.A., Cline G.W., Zhang D., Cardone R.L., Petersen K.F., Kibbey R.G., Goodman N.A.B.A.L., Shulman R.J.P.L.P.G.W.C.R.L.C.K.F.P.R.G.K.G.I. Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome. Nat. Cell Biol. 2016;534:213–217. doi: 10.1038/nature18309. PubMed DOI PMC

Vinolo M.A.R., Rodrigues H.G., Fock R.A., Malheiros G., Dos Santos M.F., Curi R., Festuccia W.T.L., Crisma A.R., Alves V.S., Martins A.R., et al. Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. Am. J. Physiol. Endocrinol. Metab. 2012;303:E272–E282. doi: 10.1152/ajpendo.00053.2012. PubMed DOI

Weitkunat K., Stuhlmann C., Postel A., Rumberger S., Fankhänel M., Woting A., Petzke K.J., Gohlke S., Schulz T.J., Blaut M., et al. Short-chain fatty acids and inulin, but not guar gum, prevent diet-induced obesity and insulin resistance through differential mechanisms in mice. Sci. Rep. 2017;7:1–13. doi: 10.1038/s41598-017-06447-x. PubMed DOI PMC

Park J., Kim M., Kang S.G., Jannasch A.H., Cooper B., Patterson J., Kim C.H. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR–S6K pathway. Mucosal Immunol. 2015;8:80–93. doi: 10.1038/mi.2014.44. PubMed DOI PMC

Kim M.H., Kang S.G., Park J.H., Yanagisawa M., Kim C.H. Short-Chain Fatty Acids Activate GPR41 and GPR43 on Intestinal Epithelial Cells to Promote Inflammatory Responses in Mice. Gastroenterology. 2013;145:396–406.e10. doi: 10.1053/j.gastro.2013.04.056. PubMed DOI

Balmer M.L., Ma E.H., Bantug G.R., Grählert J., Pfister S., Glatter T., Jauch A., Dimeloe S., Slack E., Dehio P., et al. Memory CD8+ T Cells Require Increased Concentrations of Acetate Induced by Stress for Optimal Function. Immunity. 2016;44:1312–1324. doi: 10.1016/j.immuni.2016.03.016. PubMed DOI

Müller M., Hernández M.A.G., Goossens G.H., Reijnders D., Holst J.J., Jocken J.W.E., Van Eijk H., Canfora E.E., Blaak E.E. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci. Rep. 2019;9:1–9. doi: 10.1038/s41598-019-48775-0. PubMed DOI PMC

Watanabe-Suzuki K., Seno H., Ishii A., Kumazawa T., Suzuki O. Ultra-sensitive method for determination of ethanol in whole blood by headspace capillary gas chromatography with cryogenic oven trapping. J. Chromatogr. B Biomed. Sci. Appl. 1999;727:89–94. doi: 10.1016/S0378-4347(99)00063-8. PubMed DOI

Yuan J., Chen C., Cui J., Lu J., Yan C., Wei X., Zhao X., Li N., Li S., Xue G., et al. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. Cell Metab. 2019;30:675–688.e7. doi: 10.1016/j.cmet.2019.08.018. PubMed DOI

Jeon S., Carr R. Alcohol effects on hepatic lipid metabolism. J. Lipid Res. 2020;61:470–479. doi: 10.1194/jlr.R119000547. PubMed DOI PMC

Raucy J.L., Lasker J., Ozaki K., Zoleta V. Regulation of CYP2E1 by Ethanol and Palmitic Acid and CYP4A11 by Clofibrate in Primary Cultures of Human Hepatocytes. Toxicol. Sci. 2004;79:233–241. doi: 10.1093/toxsci/kfh126. PubMed DOI

Chen P., Miyamoto Y., Mazagova M., Lee K.-C., Eckmann L., Schnabl B. Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury. Alcohol. Clin. Exp. Res. 2015;39:2313–2323. doi: 10.1111/acer.12900. PubMed DOI PMC

Boyer J.L. Bile Formation and Secretion. Compr. Phys. 2013;3:1035–1078. doi: 10.1002/cphy.c120027. PubMed DOI PMC

David L.A., Maurice C.F., Biddinger S.B., Dutton R.J., Turnbaugh P.J., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E., Ling A.V., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–563. doi: 10.1038/nature12820. PubMed DOI PMC

Copple B.L., Li T. Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol. Res. 2016;104:9–21. doi: 10.1016/j.phrs.2015.12.007. PubMed DOI PMC

Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis. Cell. 2000;102:731–744. doi: 10.1016/S0092-8674(00)00062-3. PubMed DOI

Keitel V., Donner M., Winandy S., Kubitz R., Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun. 2008;372:78–84. doi: 10.1016/j.bbrc.2008.04.171. PubMed DOI

Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., Chalasani N., Dasarathy S., Diehl A.M., Hameed B., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965. doi: 10.1016/S0140-6736(14)61933-4. PubMed DOI PMC

Moro-Sibilot L., Blanc P., Taillardet M., Bardel E., Couillault C., Boschetti G., Traverse-Glehen A., Defrance T., Kaiserlian D., Dubois B. Mouse and Human Liver Contain Immunoglobulin A–Secreting Cells Originating From Peyer’s Patches and Directed Against Intestinal Antigens. Gastroenterology. 2016;151:311–323. doi: 10.1053/j.gastro.2016.04.014. PubMed DOI

Brown W.R., Kloppel T.M. The role of the liver in Translocation of IgA into the Gastrointestinal Tract. Immunol. Investig. 1989;18:269–285. doi: 10.3109/08820138909112242. PubMed DOI

Rogier E.W., Frantz A.L., Bruno M.E.C., Wedlund L., Cohen D.A., Stromberg A.J., Kaetzel C.S. Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. Proc. Natl. Acad. Sci. USA. 2014;111:3074–3079. doi: 10.1073/pnas.1315792111. PubMed DOI PMC

Juo Y.-Y., Livingston E.H. Testing for Nonalcoholic Fatty Liver Disease. JAMA. 2019;322:1836. doi: 10.1001/jama.2019.10696. PubMed DOI

Rinella M.E. Nonalcoholic Fatty Liver Disease. JAMA. 2015;313:2263–2273. doi: 10.1001/jama.2015.5370. PubMed DOI

Lee G., You H.J., Bajaj J.S., Joo S.K., Yu J., Park S., Kang H., Park J.H., Kim J.H., Lee D.H., et al. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat. Commun. 2020;11:4982. doi: 10.1038/s41467-020-18754-5. PubMed DOI PMC

Caussy C., Hsu C., Schork N., Schnabl B., Brenner D.A., Sirlin C.B., Chen C.-H., Loomba R., Genetics of NAFLD in Twins Consortium. Lo M.-T., et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018;68:918–932. doi: 10.1002/hep.29892. PubMed DOI PMC

Bajaj J.S., Salzman N.H., Lee H., Osman M., Siddiqui M.S., Fuchs M., Puri P., Sikaroodi M., Gillevet P.M., Acharya C., et al. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. Hepatology. 2019;70:1690–1703. doi: 10.1002/hep.30690. PubMed DOI PMC

Philips C.A., Pande A., Shasthry S.M., Jamwal K.D., Khillan V., Chandel S.S., Kumar G., Sharma M.K., Maiwall R., Jindal A., et al. Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study. Clin. Gastroenterol. Hepatol. 2017;15:600–602. doi: 10.1016/j.cgh.2016.10.029. PubMed DOI

Degnan F.H. Clinical studies involving probiotics. Gut Microbes. 2012;3:485–489. doi: 10.4161/gmic.22158. PubMed DOI PMC

Gibson G.R., Roberfroid M.B. Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. J. Nutr. 1995;125:1401–1412. doi: 10.1093/jn/125.6.1401. PubMed DOI

Vamanu E. Complementary Functional Strategy for Modulation of Human Gut Microbiota. Curr. Pharm. Des. 2019;24:4144–4149. doi: 10.2174/1381612824666181001154242. PubMed DOI

Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J., Scott K., Stanton C., Swanson K.S., Cani P.D., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491–502. doi: 10.1038/nrgastro.2017.75. PubMed DOI

Sharpton S.R., Maraj B., Harding-Theobald E., Vittinghoff E., Terrault N.A. Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression. Am. J. Clin. Nutr. 2019;110:139–149. doi: 10.1093/ajcn/nqz042. PubMed DOI PMC

Duan Y., Llorente C., Lang S., Brandl K., Chu H., Jiang L., White R.C., Clarke T.H., Nguyen K., Torralba M., et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575:505–511. doi: 10.1038/s41586-019-1742-x. PubMed DOI PMC

Wang Z., Roberts A.B., Buffa J.A., Levison B.S., Zhu W., Org E., Gu X., Huang Y., Zamanian-Daryoush M., Culley M.K., et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell. 2015;163:1585–1595. doi: 10.1016/j.cell.2015.11.055. PubMed DOI PMC

Cipriani S., Mencarelli A., Palladino G., Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 2010;51:771–784. doi: 10.1194/jlr.M001602. PubMed DOI PMC

Fickert P., Fuchsbichler A., Moustafa T., Wagner M., Zollner G., Halilbasic E., Stöger U., Arrese M., Pizarro M., Solís N., et al. Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts. Am. J. Pathol. 2009;175:2392–2405. doi: 10.2353/ajpath.2009.090114. PubMed DOI PMC

Verbeke L., Farre R., Laleman W., Trebicka J., Komuta M., Roskams T., Klein S., Elst I.V., Windmolders P., Vanuytsel T., et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286–2298. doi: 10.1002/hep.26939. PubMed DOI

Harrison S.A., Rinella M.E., Abdelmalek M.F., Trotter J.F., Paredes A.H., Arnold H.L., Kugelmas M., Bashir M.R., Jaros M.J., Ling L., et al. NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;391:1174–1185. doi: 10.1016/S0140-6736(18)30474-4. PubMed DOI

Synergistic Effects of Fructose and Food Preservatives on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Gut Microbiome Alterations to Hepatic Gene Expression

Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options